Genfit SA GNFT

Financial Highlights Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028€21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement Key Highlights PBC: Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to €1 billion, underscoring the value creation potential of GENFIT's licensing agreementMASH: Medicare coverage secured in August 2026 in the United

GENFIT's acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needsThe investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset's profile: Strong knowledge of nangibotide’s biological pathwayMultiple efficacy signals already observed with nangibotide across three Phase 2 clinical trials in septic shock and COVID-19 subjects, includ

Lille (France), Cambridge (Massachusetts, United States), September 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit GENFIT to the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, September 18, 2026.

Lille (France), Cambridge (Massachusetts, United States), September 10, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that management will participate in the upcoming H.C. Wainwright 28th Annual Global Investment Conference. Conference Details:H.C. Wainwright 28th Annual Global Investment ConferenceDate: September 15, 2026, at 11:00am ET Location: New York City, NYFormat: Pre

Simple, reliable and scalable blood-based testing could identify patients with at-risk MASH among nearly 90 million U.S. individuals receiving medical attention due to MASLD-related risk factorsIQVIA estimates U.S peak sales of products based on NISTM Technology could exceed USD 1.5 billion by 2033, creating the potential for a meaningful long-term royalty-based stream for GENFITThe foundations for broader adoption of GENFIT's NISTM Technology will progressively strengthen in the coming months,

Presentations will highlight the clinical utility and long-term commercial opportunity of GENFIT’s proprietary NIS platform, a non-invasive diagnostic technology for MASH Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 3, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it will host a virtual key opinion leader (KOL) event on Wednes

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2026: 65

Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered by GENFIT’s proprietary NIS4® technologyFocuses on patients at highest risk, including those with prediabetes, type 2 diabetes, obesity and dyslipidemia A technology positioned for scale at a key inflection point in the U.S. MASH market, with the first therapy already achieving near-blockbuster status in its first year and additional agents from leading

Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi)Study conducted in a heavily pretreated, high-unmet-need population of KRAS-mutated cholangiocarcinoma (CCA) patients who had progressed after one or two failed lines of prior standard-of-care therapyPhase 2 initiation on track for initiation in 2H26 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), Jun

All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026. The quorum on first convening amounted to 32.13 % and shareholders approved

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threateni

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL Congress 2026. This visibility reflects both its scientific momentum and its active involvement in the ACLF ecosystem, as well as its position at an inflection point in MASH, while also highlighting the continuo

Cash and cash equivalents totaled €136.1 million as of March 31, 2026€9.6 million in revenue for the first three months of 2026, from royalties on Ipsen’s sales of Iqirvo® (elafibranor)Positive momentum across all growth platforms, combining increased revenue visibility and upside optionality: An established revenue stream with PBC and an emerging revenue stream with MASH diagnostics, supported by solid regulatory and commercial execution across our partner‑led programs, together with near‑term

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 French legal announcements bulletin n°56 (Bulletin des Annonces Légales Obligatoires - BALO) the notice of the Combined Shareholders Meeting, which will be held on June 15, 2026, at 10:00 am (CET), at the F

European equities traded in the US as American depositary receipts were tracking lower late Friday m